WR1 General Discussion, page-9708

It certainly wouldn't do any harm to provide at least an operations update, including the latest assay delivery forecast from the lab. I recall from my few years in CXO that shareholders were most often similarly peeved by lack of regular info from management. Even then assay results, resource upgrades, etc, were invariably way behind predicted timelines that were always on the optimistic side. Notification that management are buying a few additional shares on market at these seemingly bargain prices would be helpful too.